1. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765, (Review).
2. Chernoff AE, Granowitz EV, Shapiro L et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 15:154(10):5492-9.
3. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy—review of a new approach. Pharmacol Rev 2003; 55(2):241-69, (Review).
4. Tilg H, van Montfrans C, van den Ende A et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002;
5. Hutchings A, Wu J, Asiedu C et al. The immune decision toward allograft tolerance in nonhuman primates requires early inhibition of innate immunity and induction of immune regulation. Transpl Immunol 2003; 11(3-4):335-44.
6. Donckier V, Loi P, Closset J et al. Preconditioning of donors with interleukin-10 reduces hepatic ischemia-reperfusion injury after liver transplantation in pigs. Transplantation 2003; 75(6):902-4.
7. Li W, Fu F, Lu L et al. Differential effects of exogenous interleukin-10 on cardiac allograft survival: Inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function. Transplantation 1999; 68(9):1402-9.
8. Zou XM, Yagihashi A, Hirata K et al. Downregulation of cytokine-induced neutrophil chemoattractant and prolongation of rat liver allograft survival by interleukin-10. Surg Today 1998;
9. Eye Bank Association of America (1998). Eye Bank Association of America Annual Report: 1997-1998.
10. Torres PF, de Vos AF, Martins B et al. Interleukin 10 treatment does not prolong experimental corneal allograft survival. Ophthalmic Res 1999; 31:297-303.
11. Wissing KM, Morelon E, Legendre C et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation 1997; 64:999-1006.
12. Bacchetta R, Bigler M, Touraine JL et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179(2):493-502.
13. Baker KS, Roncarolo MG, Peters C et al. High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths. Bone Marrow Transplant 1999; 23(11):1123-9.
14. Holler E, Roncarolo MG, Hintermeier-Knabe R et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25(3):237-41.
15. Roncarolo MG, Bacchetta R, Bordignon C et al. Type 1 T regulatory cells. Immunol Rev 2001; 182:68-79, (Review).
16. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7(1):33-40, (Review).
17. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 28:288(5466):669-72.
18. Nishikawa M, Huang L. Nonviral vectors in the new millennium: Delivery barriers in gene transfer. Hum Gene Ther 2001; 12(8):861-70, (Review).
19. Walther W, Stein U. Viral vectors for gene transfer: A review of their use in the treatment of human diseases. Drugs 2000; 60:249-71, (Review).
20. de Waal Malefyt R, Abrams J, Bennett B et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991a; 174(5):1209-20.
21. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991b; 174(4):915-24.
22. DeBruyne LA, Li K, Chan SY et al. Lipid-mediated gene transfer of viral IL-10 prolongs vascular-ized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther 1998; 5(8):1079-87.
23. Hong YS, Laks H, Cui G et al. Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J Heart Lung Transplant 2002; 21(11):1188-200.
24. Itano H, Mora BN, Zhang W et al. Lipid-mediated ex vivo gene transfer of viral interleukin 10 in rat lung allotransplantation. J Thorac Cardiovasc Surg 2001; 122(1):29-38.
25. Konig Merediz SA, Zhang EP, Wittig B et al. Hoffmann F. Ballistic transfer of minimalistic im-munologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. Graefes Arch Clin Exp Ophthalmol 2000; 238(8):701-7.
26. Fischbein MP, Yun J, Laks H et al. Regulated interleukin-10 expression prevents chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg 2003; 126(1):216-23.
27. Qin L, Chavin KD, Ding Y et al. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Immunosuppression with TGF-beta 1 or vIL-10. Transplantation 1995; 27:59(6):809-16.
28. Brauner R, Nonoyama M, Laks H et al. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J Thorac Cardiovasc Surg 1997; 114(6):923-33.
29. Qin L, Ding Y, Pahud DR et al. Adenovirus-mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum Gene Ther 1997; 8(11):1365-74.
30. Ding Y, Qin L, Kotenko SV et al. A single amino acid determines the immunostimulatory activity of interleukin 10. J Exp Med 2000; 191(2):213-24.
31. David A, Chetritt J, Guillot C et al. Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats. Gene Ther 2000; 7(6):505-10.
32. Fischer S, Liu M, MacLean AA et al. In vivo transtracheal adenovirus-mediated transfer of human interleukin-10 gene to donor lungs ameliorates ischemia-reperfusion injury and improves early posttransplant graft function in the rat. Hum Gene Ther 2001; 12:1513-1526.
33. Klebe S, Sykes PJ, Coster DJ et al. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001; 71:1214-1220.
34. Kato H, Fieblinger C, Ke B et al. Synergistic effects of cytokine gene transfer in high responder rat renal allograft recipients. Transplantation 1999; 67:S570.
35. Goudy K, Song S, Wasserfall C et al. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA 2001; 98:13913-13918.
36. Yang Z, Chen M, Wu R et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 2002; 168:6479-6485.
37. Zhang YC, Pileggi A, Agarwal A et al. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 2003; 52:708-716.
38. Takayama T, Nishioka Y, Lu L et al. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998; 66:1567-1574.
39. Coates PT, Krishnan R, Kireta S et al. Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice. Gene Ther 2001; 8:1224-1233.
40. Lee WC, Qiani S, Wan Y et al. Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection. Immunology 2000; 101:233-241.
40a. Van Montfraus C, Rodriguez Pena MS, Prouk I et al. Prevention of colitis by interleukin-10 transduced T lymphocytes in the SCID mice transfer model. Gastroenterology 2002; 123:(6):1865-1876.
41. Murakami Y, Akahoshi T, Kawai S et al. Antiinflammatory effect of retrovirally transfected interleukin-10 on monosodium urate monohydrate crystal-induced acute inflammation in murine air pouches. Arthritis Rheum 2002; 46:2504-2513.
42. Oh JW, Seroogy CM, Meyer EH et al. CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. J Allergy Clin Immunol 2002; 110:460-468.
43 Hall BM, Jelbart ME, Gurley KE et al. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/ inducer cells. J Exp Med 1985; 162:1683-1694.
44. Qin S, Cobbold SP, Pope H et al. "Infectious" transplantation tolerance. Science 1993; 259:974-977.
45. Onodera K, Lehmann M, Akalin E et al. Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J Immunol 1996; 157:1944-1950.
46. Zhai Y, Kupiec-Weglinski JW. What is the role of regulatory T cells in transplantation tolerance? Curr Opin Immunol 1999; 11:497-503, (Review).
47. Waldmann H, Cobbold S. Regulating the immune response to transplants. A role for CD4+ regulatory cells? Immunity 2001; 14:399-406, (Review).
48. Battaglia M, Blazar BR, Roncarolo MG. The puzzling world of murine T regulatory cells. Microbes Infect 2002; 4:559-66, (Review).
49. Karim M, Bushell AR, Wood KJ. Regulatory T cells in transplantation. Curr Opin Immunol 2002; 14:584-591.
50. Levings MK, Bacchetta R, Schulz U et al. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129:263-276.
51. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002; 2:389-400.
52. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199-210.
53. Hara M, Kingsley CI, Niimi M et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166(6):3789-96.
54. Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-742.
55. Chen ZM, O'Shaughnessy MJ, Gramaglia I et al. IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood 2003; 101:5076-5083.
56. Barrat FJ, Cua DJ, Boonstra A et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med 2002; 4:195(5):603-16.
57. Nussler NC, Muller AR, Weidenbach H et al. IL-10 increases tissue injury after selective intestinal ischemia/reperfusion. Ann Surg 2003; 238(1):49-58.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.